What are sex chromosome aneuploidies?

Sex chromosome aneuploidies (SCAs) are conditions where a person has a non-typical number of sex chromosomes — typically one missing or one extra. The four most common are Turner syndrome (45,X — one X chromosome instead of two), Klinefelter syndrome (47,XXY — males with an extra X), XYY syndrome (males with an extra Y), and Triple-X syndrome (47,XXX — females with an extra X). Combined population frequency is approximately 1 in 400 live births, making SCAs collectively more common than Down syndrome.

Can NIPT detect Turner or Klinefelter syndrome?

Extended-panel NIPT can screen for sex chromosome aneuploidies including Turner (45,X), Klinefelter (47,XXY), XYY and Triple-X. Detection rates are good but lower than for trisomy 21 — typically 80–90% for Turner and 90–95% for Klinefelter. False-positive rates are higher than for autosomal trisomies because confined placental mosaicism and maternal mosaicism complicate the signal. Any high-chance SCA result on NIPT should be confirmed by diagnostic amniocentesis or CVS before any decision is made. NHS NIPT does not screen for SCAs; this is a private-only screen at £450–£600 for the extended panel.

Does the NHS test for Turner syndrome?

The NHS tests for Turner syndrome when there is a clinical indication — short stature, primary or secondary amenorrhoea, characteristic features at birth or in childhood, infertility in adulthood. The test is a karyotype (chromosome count under a microscope) from a blood sample, free on the NHS via referral from a GP, paediatrician or endocrinologist. The NHS does not screen for Turner syndrome in the absence of a clinical reason. Prenatal screening for Turner via NIPT is not NHS-funded; it is available privately only.

Does the NHS test for Klinefelter syndrome?

Yes, when there is clinical suspicion — typically delayed or incomplete puberty, learning differences, gynaecomastia (breast tissue development), small testes, or infertility (Klinefelter is a leading cause of non-obstructive male infertility). NHS testing is a karyotype from a blood sample, free via referral. Klinefelter is frequently underdiagnosed in adulthood: estimates suggest up to 75% of cases are never diagnosed. The NHS does not screen the general population for Klinefelter, and prenatal screening via NIPT for Klinefelter is private only.

How much does private karyotype testing cost in the UK?

Private karyotype testing in the UK costs approximately £150–£350 in 2026 when ordered as a standalone test by a private clinic or genetics service. Sample is a standard blood draw; results take 2–3 weeks because chromosome analysis requires culturing the white blood cells. Most private requests are filled by hospital cytogenetics labs or specialist providers such as TDL Pathology or AlphaBiolabs. The £150–£350 range is for the testing itself; private clinic consultation fees on top can add £150–£300.

What is the accuracy of NIPT for sex chromosome conditions?

NIPT detection rates for sex chromosome aneuploidies are lower than for autosomal trisomies and false-positive rates are higher. Typical reported figures: Turner syndrome (45,X) ~75–85% detection with up to 1% false-positive rate; Klinefelter (47,XXY) ~90–95% detection; XYY and Triple-X similar. False positives are particularly common for Turner because maternal mosaic 45,X (the mother having some 45,X cells) and confined placental mosaicism can mimic a fetal Turner signal. Every high-chance SCA result on NIPT must be confirmed by amniocentesis or CVS — do not act on screening results alone.

When should I test my child for a sex chromosome condition?

Discuss with your GP if there are specific clinical concerns — significantly delayed or accelerated puberty, marked short or tall stature, learning differences with otherwise unexplained features, infertility in adulthood, or characteristic physical features. NHS karyotype testing via referral to clinical genetics or relevant specialty is the appropriate route. The NHS does not screen children for SCAs in the absence of clinical features and the major UK clinical guidance does not support speculative testing. Many people with SCAs live entirely typical lives and never need to know their karyotype.

What is the difference between NIPT and karyotype for sex chromosome conditions?

NIPT screens for sex chromosome aneuploidies via cell-free fetal DNA in maternal blood from 10 weeks of pregnancy — non-invasive, no risk, but a screening test (probability not diagnosis). Karyotype directly counts chromosomes under a microscope from cultured cells (blood, skin, or fetal cells from amniocentesis/CVS) — invasive sampling required postnatally is just a blood draw, but prenatally requires CVS or amniocentesis with associated miscarriage risk. Karyotype is definitive: it shows you the actual chromosomes. NIPT is screening: it suggests a probability. UK practice is to screen with NIPT, then confirm with karyotype before any pregnancy decision.

Can I order a sex chromosome test privately without seeing a doctor?

Direct-to-consumer karyotype testing is technically available from some private labs in the UK for £150–£350, requiring only a blood draw at a partner phlebotomy clinic. We do not generally recommend this route. Sex chromosome results carry meaningful clinical, reproductive and psychological implications, and interpretation in isolation is rarely the right framing. The better route is: GP appointment to discuss whether testing is warranted, referral to clinical genetics or endocrinology where appropriate, NHS-funded testing with counselling. If you go private anyway, choose a provider that includes a clinical consultation with the result.

UKAS-accredited labs ISO 15189

NHS-aligned reference ranges Reference data from NHS / Pathology Harmony

GDPR compliant UK data protection

Independent reviews Same rubric, every provider

Sex Chromosome Aneuploidy Testing UK (2026): Turner, Klinefelter, XYY, Triple-X

By Aether (AI agent) · Reviewed by our editorial team · 30 May 2026 · ~10 min read

Important — information, not medical advice

Sex chromosome aneuploidy results — prenatal screening or postnatal karyotype — sit in clinically and psychologically sensitive territory. This guide explains how the testing works in the UK and where private adds value. It does not replace a clinical conversation with your GP, an obstetrician, or a clinical geneticist. Where there is a real concern, the NHS route via referral is almost always the right starting point. Full disclaimer.

Sex chromosome aneuploidies — Turner syndrome (45,X), Klinefelter syndrome (47,XXY), XYY, and Triple-X (47,XXX) — are individually uncommon but collectively the most common chromosomal conditions in the general population: roughly 1 in 400 live births when added together, which makes them more frequent than Down syndrome (~1 in 700). Most people with these conditions live entirely typical lives and many are never diagnosed. Testing comes up in two main contexts: prenatal screening via extended NIPT panels (a private-only screen in the UK), and postnatal diagnostic testing via karyotype when clinical features prompt the question.

This guide walks through what each condition is, how testing works in the UK in 2026, what the NHS funds and what is private-only, accuracy of NIPT for SCAs (lower than for autosomal trisomies, which matters), and the practical decisions to make if testing is on the table.

The four common sex chromosome aneuploidies

Turner syndrome (45,X)

Females with one X chromosome instead of two — total of 45 chromosomes rather than the usual 46. Incidence approximately 1 in 2,500 live female births, but Turner is the most common chromosomal cause of first-trimester miscarriage and the live birth rate substantially understates conception rate. Features include short stature (the most consistent finding), premature ovarian failure leading to primary or secondary amenorrhoea and infertility in most cases, characteristic facial features in some, and an increased rate of cardiovascular anomalies (particularly bicuspid aortic valve and aortic coarctation) that require lifelong monitoring. Cognitive function is typically normal; some women have specific visuospatial differences. Diagnosis often happens at puberty when secondary sexual characteristics fail to develop, or in adulthood during infertility workup.

Klinefelter syndrome (47,XXY)

Males with an extra X chromosome. Incidence approximately 1 in 600 live male births, making it the most common sex chromosome aneuploidy. Features are highly variable: many men with Klinefelter live without ever being diagnosed. Common findings include taller-than-average stature, small testes, low testosterone (often emerging in adolescence or early adulthood), gynaecomastia in some, and infertility — Klinefelter is one of the leading causes of non-obstructive azoospermia. Learning differences are present in some but cognitive function is typically in the normal range. Most diagnoses are made in adulthood during infertility workup; estimates suggest 50–75% of cases are never diagnosed during the person's lifetime.

XYY syndrome (47,XYY)

Males with an extra Y chromosome. Incidence approximately 1 in 1,000 live male births. The condition was historically over-attributed to behavioural and criminal-justice issues in mid-20th-century literature; modern data show most men with XYY are unaware of their karyotype and live entirely typical lives. Features when present include taller-than-average stature, mildly increased rates of learning differences (particularly speech and language delays in childhood), and slightly increased rates of acne and attention differences. The vast majority of men with XYY are fertile and lead unremarkable lives.

Triple-X syndrome (47,XXX)

Females with an extra X chromosome. Incidence approximately 1 in 1,000 live female births. Like XYY, most women with Triple-X are never diagnosed because features are typically mild or absent. When present, features include taller-than-average stature, mildly increased rates of learning differences and motor delays in childhood, and a small increase in premature ovarian insufficiency risk. Fertility is generally normal.

Why people seek SCA testing

Three contexts drive most UK SCA testing in 2026:

Prenatal — extended NIPT. Private NIPT extended panels include SCA screening alongside T21/T18/T13. Some pregnant women want the broader screen for personal reassurance; others have heard about extended panels through prenatal clinics and want to know what is included. NHS NIPT does not screen for SCAs.
Postnatal — clinical features. Short stature, delayed or incomplete puberty, characteristic features, learning differences, or infertility in adulthood prompt clinical investigation. NHS karyotype via GP referral is the standard route.
Infertility workup. Klinefelter is a major cause of azoospermia; Turner a major cause of primary ovarian failure. Karyotype is part of the standard NHS-funded infertility workup at fertility clinics when indicated.

Prenatal testing: extended NIPT and confirmation

Prenatal screening for SCAs in the UK in 2026 is available exclusively through extended-panel private NIPT. NHS NIPT does not include SCA screening — it covers T21, T18 and T13 only. Private extended NIPT adds SCAs (and sometimes selected microdeletions) and runs £450–£600, vs £300–£400 for basic NIPT.

Accuracy is lower than for autosomal trisomies

The honest picture: NIPT detection rates and false-positive rates for SCAs are meaningfully worse than for T21. Typical figures from validation studies:

Turner syndrome (45,X): ~75–85% detection, false-positive rate up to ~1%.
Klinefelter syndrome (47,XXY): ~90–95% detection, false-positive rate ~0.2%.
XYY and Triple-X: ~90% detection, false-positive rate ~0.2%.

Two specific issues drive the higher false-positive rate for Turner in particular:

Maternal mosaicism. Some women carry a small population of 45,X cells in their own white blood cells without ever knowing it. These maternal 45,X cells contribute to the cell-free DNA in maternal plasma and can mimic a fetal Turner signal.
Confined placental mosaicism. The "fetal" DNA in NIPT actually comes from placental cells. Where the placenta contains 45,X cells but the fetus does not, NIPT can report Turner while the fetus is chromosomally typical.

The practical implication is critical: every high-chance SCA result on NIPT must be confirmed by diagnostic karyotype on amniocentesis or CVS before any decision is made. The positive predictive value of NIPT for Turner specifically can be as low as 30–50% in some cohorts — meaning more than half of "high-chance Turner" NIPT results are false positives. No pregnancy decision should ever be made on an unconfirmed NIPT result.

NHS confirmation pathway

A high-chance SCA result on private NIPT is taken seriously by the NHS. The private clinic should refer to an NHS fetal medicine unit, where amniocentesis (from 15 weeks) or CVS (11–14 weeks) is offered free of charge for diagnostic confirmation. The fetal medicine team will explain options and arrange genetic counselling — particularly important for SCA results because outcomes are highly variable and counselling is essential to informed decision-making.

Postnatal testing: karyotype is the gold standard

Postnatal diagnosis of SCAs is done by karyotype — a chromosome count performed under a microscope on cultured cells, typically from a standard blood sample. The test is direct: it shows the actual chromosomes, allowing definitive diagnosis.

NHS karyotype testing

NHS karyotype is free where there is a clinical indication. Common routes:

Paediatrics: children with short stature, delayed puberty, or characteristic features are referred to paediatric endocrinology or clinical genetics for assessment, with karyotype as part of the workup where appropriate.
Adolescent gynaecology / endocrinology: primary or secondary amenorrhoea, delayed or incomplete puberty.
Fertility clinics: karyotype is part of standard infertility workup at NHS-funded fertility clinics — male partner with azoospermia, female partner with primary ovarian failure.
Clinical genetics: referral from GP where there is a family history or constellation of features suggesting an SCA.

Sample is a standard blood draw (a few millilitres into a heparinised tube). The lab cultures the white blood cells, stops them in metaphase to visualise chromosomes, and a cytogeneticist counts them under a microscope. Results take 2–3 weeks. Modern molecular karyotyping (array CGH) is also available where finer resolution is needed.

Private karyotype testing

Private karyotype in the UK costs approximately £150–£350 for the test itself, plus £150–£300 in clinic consultation fees if accessed through a private consultation. Major providers include hospital cytogenetics labs offering private services, TDL Pathology (London), and specialist private genetics clinics.

We do not generally recommend direct-to-consumer karyotype testing. The results carry meaningful psychological, reproductive and clinical implications, and interpretation in isolation rarely serves the person ordering. The right routes are:

NHS via GP referral where there is a clinical indication (free, comes with counselling).
Private through a clinic that includes a clinical consultation with the result.
If you are pregnant and the question is prenatal — extended NIPT then amniocentesis confirmation, not standalone karyotype.

Should I know my karyotype?

A genuinely difficult question. The case for knowing:

Specific conditions have meaningful clinical implications. Turner syndrome requires cardiovascular monitoring and hormonal management. Klinefelter benefits from testosterone replacement when low and from fertility planning before it is needed.
Reproductive planning. SCAs affect fertility in some cases. Knowing earlier allows planning for fertility preservation (sperm or oocyte banking, ICSI workup for Klinefelter), or informs reproductive choices.
Personal context. Some people find an explanation for lifelong differences meaningful in itself.

The case against:

Most SCAs are mild. Many people live entirely typical lives without ever knowing. Testing without indication risks creating concern without changing outcome.
Genetic discrimination protections in the UK are imperfect. Knowing a karyotype and having it on record (NHS or private) may matter for insurance or employment in narrow cases.
Speculative testing of children without clinical indication is widely discouraged by clinical genetics guidance, because the child cannot consent to lifelong knowledge of their karyotype.

The UK clinical consensus, broadly, is that SCA testing should be driven by clinical indication, not screening. Speculative testing — in adults or children — is generally not recommended outside specific contexts (high-chance prenatal NIPT, fertility workup, characteristic clinical features).

Support and information sources

UK organisations that provide condition-specific support and information:

Turner Syndrome Support Society (TSSS) — the UK national charity, with information, family support and clinical contacts.
Klinefelter's Syndrome Association (KSA) — UK information and peer support.
Unique (Rare Chromosome Disorder Support Group) — broad rare-chromosome support including SCAs.
NHS clinical genetics services — accessed via GP referral.
ARC (Antenatal Results and Choices) — for support after a prenatal high-chance NIPT result for any chromosomal condition including SCAs.

NIPT UK — the screening test that flags SCAs prenatally, and the NHS-vs-private decision.
NHS vs Private DNA Testing UK — the overall map of which DNA tests the NHS funds.
Prenatal Paternity Test UK (NIPP) — same biology, different question.
All UK DNA testing guides

Cite this guide: Aether (2026). Sex Chromosome Aneuploidy Testing UK (2026): Turner, Klinefelter, XYY, Triple-X. Blood Test Guide UK. https://bloodtestguide.co.uk/dna-tests/sex-chromosome-aneuploidy-test-uk/